ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "1e3f3827-71b8-4934-8e1d-df90e1b17213"}, "_deposit": {"id": "27350", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "27350"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00027350", "sets": ["2359"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "102", "bibliographicPageStart": "93", "bibliographicVolumeNumber": "81", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite multiple treatment strategies, the prognosis is still poor. This study aimed to evaluate the efficacy of combination treatment of GBM with the histone deacetylase (HDAC) inhibitor panobinostat and dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235. GBM cells were exposed to panobinostat and BEZ235 treatment alone or in combination, after which cell viability, proliferation and apoptosis were detected. Furthermore, the inhibitory mechanisms were investigated by Caspase-Glo assay, Western blot and qPCR analysis. We found that combination treatment with panobinostat and BEZ235 synergistically inhibited cell viability, markedly inhibited cell proliferation and induced apoptosis in GBM cells. Mechanistically, cotreatment with panobinostat and BEZ235 increased caspase 3/7 activity, suppressed proliferation- and antiapoptosis-related markers and AKT signaling in GBM cells. Cotreatment with panobinostat and BEZ235 warrants further evaluation in GBM therapy. ", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.81.1.93", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/811.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Meng, Wei"}], "nameIdentifiers": [{"nameIdentifier": "89432", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wang, Baocheng"}], "nameIdentifiers": [{"nameIdentifier": "89433", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mao, Weiwei"}], "nameIdentifiers": [{"nameIdentifier": "89434", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wang, Jiajia"}], "nameIdentifiers": [{"nameIdentifier": "89435", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhao, Yang"}], "nameIdentifiers": [{"nameIdentifier": "89436", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Li, Qifeng"}], "nameIdentifiers": [{"nameIdentifier": "89437", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-03-15"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "08_Wei_Meng.pdf", "filesize": [{"value": "7.7 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 7700000.0, "url": {"label": "08_Wei_Meng.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/27350/files/08_Wei_Meng.pdf"}, "version_id": "07fa9bc4-c99e-44de-8a14-fa940d9e13ef"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "glioblastoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "panobinostat", "subitem_subject_scheme": "Other"}, {"subitem_subject": "BEZ235", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma"}]}, "item_type_id": "9", "owner": "1", "path": ["2359"], "permalink_uri": "https://doi.org/10.18999/nagjms.81.1.93", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-03-15"}, "publish_date": "2019-03-15", "publish_status": "0", "recid": "27350", "relation": {}, "relation_version_is_last": true, "title": ["Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 81(1)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma

https://doi.org/10.18999/nagjms.81.1.93
https://doi.org/10.18999/nagjms.81.1.93
e2ef9bb0-a303-401e-ba7d-27a7b0a0dd9c
名前 / ファイル ライセンス アクション
08_Wei_Meng.pdf 08_Wei_Meng.pdf (7.7 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2019-03-15
タイトル
タイトル Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
著者 Meng, Wei

× Meng, Wei

WEKO 89432

Meng, Wei

Search repository
Wang, Baocheng

× Wang, Baocheng

WEKO 89433

Wang, Baocheng

Search repository
Mao, Weiwei

× Mao, Weiwei

WEKO 89434

Mao, Weiwei

Search repository
Wang, Jiajia

× Wang, Jiajia

WEKO 89435

Wang, Jiajia

Search repository
Zhao, Yang

× Zhao, Yang

WEKO 89436

Zhao, Yang

Search repository
Li, Qifeng

× Li, Qifeng

WEKO 89437

Li, Qifeng

Search repository
キーワード
主題Scheme Other
主題 glioblastoma
キーワード
主題Scheme Other
主題 panobinostat
キーワード
主題Scheme Other
主題 BEZ235
抄録
内容記述 Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite multiple treatment strategies, the prognosis is still poor. This study aimed to evaluate the efficacy of combination treatment of GBM with the histone deacetylase (HDAC) inhibitor panobinostat and dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235. GBM cells were exposed to panobinostat and BEZ235 treatment alone or in combination, after which cell viability, proliferation and apoptosis were detected. Furthermore, the inhibitory mechanisms were investigated by Caspase-Glo assay, Western blot and qPCR analysis. We found that combination treatment with panobinostat and BEZ235 synergistically inhibited cell viability, markedly inhibited cell proliferation and induced apoptosis in GBM cells. Mechanistically, cotreatment with panobinostat and BEZ235 increased caspase 3/7 activity, suppressed proliferation- and antiapoptosis-related markers and AKT signaling in GBM cells. Cotreatment with panobinostat and BEZ235 warrants further evaluation in GBM therapy.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.81.1.93
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/811.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 81, 号 1, p. 93-102, 発行日 2019-02
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 10:38:26.496830
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3